WA
ALXN

WFG Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

WFG Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$0 Hold
1
– – ﹤0.01% 1709
2017
Q1 		$0 Hold
1
– – ﹤0.01% 1718
2016
Q4 		$0 Sell
1
-6
-86% -$734 ﹤0.01% 1784
2016
Q3 		$1K Hold
7
– – ﹤0.01% 1525
2016
Q2 		$1K Hold
7
– – ﹤0.01% 1517
2016
Q1 		$1K Buy
7
+1
+17% +$147 ﹤0.01% 1480
2015
Q4 		$1K Hold
6
– – ﹤0.01% 1517
2015
Q3 		$1K Hold
6
– – ﹤0.01% 1548
2015
Q2 		$1K Hold
6
– – ﹤0.01% 1611
2015
Q1 		$1K Sell
6
-170
-97% -$30.8K ﹤0.01% 1686
2014
Q4 		$33K Hold
176
– – 0.01% 1057
2014
Q3 		$29K Sell
176
-400
-69% -$65.7K 0.01% 1143
2014
Q2 		$90K Hold
576
– – 0.02% 696
2014
Q1 		$88K Hold
576
– – 0.02% 688
2013
Q4 		$77K Buy
576
+500
+658% +$60K 0.01% 845
2013
Q3 		$9K Hold
76
– – ﹤0.01% 1576
2013
Q2 		$7K Buy
+76
New +$7.32K ﹤0.01% 1583

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

WFG Advisors's ALXN Position: Q2 2017 in Review

WFG Advisors held its Alexion Pharmaceuticals (ALXN) position steady in Q2 2017 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

WFG Advisors first reported a position in ALXN in Q2 2013 and has held it in 17 quarters since. The position peaked at $90K in Q2 2014. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • WFG Advisors held 1 share of Alexion Pharmaceuticals worth $0 as of Q2 2017.
  • WFG Advisors left its Alexion Pharmaceuticals share count unchanged in Q2 2017.
  • Alexion Pharmaceuticals made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1709 holding.
  • WFG Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • WFG Advisors's Alexion Pharmaceuticals position peaked at $90K in Q2 2014.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.